tirzepatide injection site itching Tirzepatide-Induced Reaction Mounjaro injection site reaction?

FLOW trial of Semaglutide, source: Novo Nordisk official website The key objective of the FLOW trial is to demonstrate delay in progression of CKD and to lower the risk of kidney and cardiovascular mortality through the composite primary endpoint consisting of the following five components: compared with baseline: 1) sustained decrease in eGFR1 50%

No diagnosis or prior treatment history is required

Additionally, it improves insulin sensitivity, making it particularly beneficial for individuals with type 2 diabetes or those at risk of developing this condition

Stable glucose levels reduce the risk of complications like nerve damage and heart disease